BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
JERUSALEM, June 12, 2020 /PRNewswire/ — BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its fourth quarter and full year financial results…
Comments Off on BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update